25 XP   0   0   10

Fulcrum Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Fulcrum Therapeutics Inc together

PenkeI guess you are interested in Fulcrum Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Fulcrum Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Fulcrum Therapeutics Inc

I send you an email if I find something interesting about Fulcrum Therapeutics Inc.

Quick analysis of Fulcrum Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Fulcrum Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
4.8%

What is your share worth?

Current worth
$3.80
Expected worth in 1 year
$4.38
How sure are you?
38.1%

+ What do you gain per year?

Total Gains per Share
$0.59
Return On Investment
8.2%

For what price can you sell your share?

Current Price per Share
$7.13
Expected price per share
$6.4 - $14.10
How sure are you?
50%

1. Valuation of Fulcrum Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$7.13

Intrinsic Value Per Share

$-13.17 - $-15.23

Total Value Per Share

$-9.37 - $-11.43

2. Growth of Fulcrum Therapeutics Inc (5 min.)




Is Fulcrum Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$235.1m$192.5m$73m27.5%

How much money is Fulcrum Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$23.5m-$26.8m$3.3m14.1%
Net Profit Margin-4,009.3%-2,070.5%--

How much money comes from the company's main activities?

3. Financial Health of Fulcrum Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#223 / 1010

Most Revenue
#526 / 1010

Most Profit
#723 / 1010

Most Efficient
#889 / 1010

What can you expect buying and holding a share of Fulcrum Therapeutics Inc? (5 min.)

Welcome investor! Fulcrum Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Fulcrum Therapeutics Inc.

What can you expect buying and holding a share of Fulcrum Therapeutics Inc?

First you should know what it really means to hold a share of Fulcrum Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Fulcrum Therapeutics Inc is $7.13. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fulcrum Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fulcrum Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.80. Based on the TTM, the Book Value Change Per Share is $0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fulcrum Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.40-5.6%-0.39-5.5%-0.44-6.2%-0.36-5.1%-0.35-5.0%
Usd Book Value Change Per Share-0.33-4.6%0.152.1%-0.05-0.7%0.131.8%0.182.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.050.7%0.050.7%
Usd Total Gains Per Share-0.33-4.6%0.152.1%-0.05-0.7%0.182.5%0.233.2%
Usd Price Per Share6.75-4.34-10.98-10.13-9.65-
Price to Earnings Ratio-4.22--2.75--6.49--7.77--7.40-
Price-to-Total Gains Ratio-20.63--10.60--21.99--15.84--15.84-
Price to Book Ratio1.78-1.05-3.54-4.53-4.31-
Price-to-Total Gains Ratio-20.63--10.60--21.99--15.84--15.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.13
Number of shares140
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.05
Usd Book Value Change Per Share0.150.13
Usd Total Gains Per Share0.150.18
Gains per Quarter (140 shares)20.4925.23
Gains per Year (140 shares)81.94100.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
108272297291
2016415458144192
3024623687216293
40328318116288394
50410400145360495
60492482174432596
70574564203504697
80656646232576798
90737728260648899
1008198102897201000

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%7.014.00.033.3%7.014.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%1.00.020.04.8%1.00.020.04.8%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%8.013.00.038.1%8.013.00.038.1%

Fundamentals of Fulcrum Therapeutics Inc

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 08:26:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Fulcrum Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fulcrum Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -2,842.3% means that $-28.42 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Fulcrum Therapeutics Inc:

  • The MRQ is -2,842.3%. The company is making a huge loss. -2
  • The TTM is -4,009.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,842.3%TTM-4,009.3%+1,167.1%
TTM-4,009.3%YOY-2,070.5%-1,938.9%
TTM-4,009.3%5Y-1,534.8%-2,474.5%
5Y-1,534.8%10Y-1,461.7%-73.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,842.3%-207.2%-2,635.1%
TTM-4,009.3%-216.8%-3,792.5%
YOY-2,070.5%-282.3%-1,788.2%
5Y-1,534.8%-436.8%-1,098.0%
10Y-1,461.7%-597.3%-864.4%
1.1.2. Return on Assets

Shows how efficient Fulcrum Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • -9.6% Return on Assets means that Fulcrum Therapeutics Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Fulcrum Therapeutics Inc:

  • The MRQ is -9.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.6%TTM-8.2%-1.4%
TTM-8.2%YOY-12.3%+4.1%
TTM-8.2%5Y-14.0%+5.8%
5Y-14.0%10Y-13.8%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.6%-13.3%+3.7%
TTM-8.2%-12.8%+4.6%
YOY-12.3%-11.6%-0.7%
5Y-14.0%-13.8%-0.2%
10Y-13.8%-15.6%+1.8%
1.1.3. Return on Equity

Shows how efficient Fulcrum Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • -10.5% Return on Equity means Fulcrum Therapeutics Inc generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Fulcrum Therapeutics Inc:

  • The MRQ is -10.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-9.0%-1.6%
TTM-9.0%YOY-14.4%+5.4%
TTM-9.0%5Y-16.8%+7.8%
5Y-16.8%10Y-16.5%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.5%-16.9%+6.4%
TTM-9.0%-16.1%+7.1%
YOY-14.4%-14.9%+0.5%
5Y-16.8%-19.3%+2.5%
10Y-16.5%-20.1%+3.6%

1.2. Operating Efficiency of Fulcrum Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fulcrum Therapeutics Inc is operating .

  • Measures how much profit Fulcrum Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -3,213.8% means the company generated $-32.14  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Fulcrum Therapeutics Inc:

  • The MRQ is -3,213.8%. The company is operating very inefficient. -2
  • The TTM is -4,898.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,213.8%TTM-4,898.4%+1,684.6%
TTM-4,898.4%YOY-2,241.1%-2,657.2%
TTM-4,898.4%5Y-1,751.8%-3,146.5%
5Y-1,751.8%10Y-1,668.4%-83.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,213.8%-298.0%-2,915.8%
TTM-4,898.4%-238.5%-4,659.9%
YOY-2,241.1%-288.4%-1,952.7%
5Y-1,751.8%-486.2%-1,265.6%
10Y-1,668.4%-628.4%-1,040.0%
1.2.2. Operating Ratio

Measures how efficient Fulcrum Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 33.14 means that the operating costs are $33.14 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Fulcrum Therapeutics Inc:

  • The MRQ is 33.138. The company is inefficient in keeping operating costs low. -1
  • The TTM is 50.319. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ33.138TTM50.319-17.181
TTM50.319YOY23.762+26.557
TTM50.3195Y18.441+31.878
5Y18.44110Y17.563+0.878
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ33.1383.235+29.903
TTM50.3193.310+47.009
YOY23.7623.838+19.924
5Y18.4415.679+12.762
10Y17.5637.823+9.740

1.3. Liquidity of Fulcrum Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fulcrum Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 17.71 means the company has $17.71 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Fulcrum Therapeutics Inc:

  • The MRQ is 17.711. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.123. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ17.711TTM19.123-1.412
TTM19.123YOY11.679+7.444
TTM19.1235Y11.311+7.813
5Y11.31110Y11.606-0.296
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.7113.863+13.848
TTM19.1234.169+14.954
YOY11.6795.337+6.342
5Y11.3116.122+5.189
10Y11.6066.434+5.172
1.3.2. Quick Ratio

Measures if Fulcrum Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 32.84 means the company can pay off $32.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Fulcrum Therapeutics Inc:

  • The MRQ is 32.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 35.451. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ32.843TTM35.451-2.608
TTM35.451YOY19.855+15.597
TTM35.4515Y17.833+17.618
5Y17.83310Y17.809+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.8433.504+29.339
TTM35.4513.991+31.460
YOY19.8555.371+14.484
5Y17.8336.088+11.745
10Y17.8096.395+11.414

1.4. Solvency of Fulcrum Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fulcrum Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fulcrum Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that Fulcrum Therapeutics Inc assets are financed with 8.7% credit (debt) and the remaining percentage (100% - 8.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Fulcrum Therapeutics Inc:

  • The MRQ is 0.087. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.083. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.087TTM0.083+0.004
TTM0.083YOY0.137-0.054
TTM0.0835Y0.152-0.069
5Y0.15210Y0.150+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0870.339-0.252
TTM0.0830.337-0.254
YOY0.1370.271-0.134
5Y0.1520.368-0.216
10Y0.1500.388-0.238
1.4.2. Debt to Equity Ratio

Measures if Fulcrum Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.6% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Fulcrum Therapeutics Inc:

  • The MRQ is 0.096. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.090. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.096TTM0.090+0.005
TTM0.090YOY0.159-0.069
TTM0.0905Y0.185-0.095
5Y0.18510Y0.183+0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0960.392-0.296
TTM0.0900.403-0.313
YOY0.1590.335-0.176
5Y0.1850.427-0.242
10Y0.1830.461-0.278

2. Market Valuation of Fulcrum Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Fulcrum Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Fulcrum Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -4.22 means the investor is paying $-4.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Fulcrum Therapeutics Inc:

  • The EOD is -4.460. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.222. Based on the earnings, the company is expensive. -2
  • The TTM is -2.753. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.460MRQ-4.222-0.238
MRQ-4.222TTM-2.753-1.468
TTM-2.753YOY-6.485+3.732
TTM-2.7535Y-7.769+5.016
5Y-7.76910Y-7.399-0.370
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.460-2.300-2.160
MRQ-4.222-2.656-1.566
TTM-2.753-2.718-0.035
YOY-6.485-4.145-2.340
5Y-7.769-6.258-1.511
10Y-7.399-6.315-1.084
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Fulcrum Therapeutics Inc:

  • The EOD is -4.751. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.498. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.936. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.751MRQ-4.498-0.253
MRQ-4.498TTM-2.936-1.562
TTM-2.936YOY-7.291+4.355
TTM-2.9365Y-11.148+8.212
5Y-11.14810Y-10.617-0.531
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.751-2.974-1.777
MRQ-4.498-3.306-1.192
TTM-2.936-3.508+0.572
YOY-7.291-5.613-1.678
5Y-11.148-8.378-2.770
10Y-10.617-8.873-1.744
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fulcrum Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.78 means the investor is paying $1.78 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Fulcrum Therapeutics Inc:

  • The EOD is 1.878. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.778. Based on the equity, the company is underpriced. +1
  • The TTM is 1.048. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.878MRQ1.778+0.100
MRQ1.778TTM1.048+0.730
TTM1.048YOY3.540-2.492
TTM1.0485Y4.528-3.480
5Y4.52810Y4.313+0.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8781.914-0.036
MRQ1.7782.116-0.338
TTM1.0482.097-1.049
YOY3.5402.881+0.659
5Y4.5283.550+0.978
10Y4.3133.936+0.377
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Fulcrum Therapeutics Inc.

3.1. Institutions holding Fulcrum Therapeutics Inc

Institutions are holding 99.1% of the shares of Fulcrum Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RA Capital Management, LLC18.74491.2241160970400
2023-12-31FMR Inc9.17830.0035684615-290801-4.8666
2023-12-31Suvretta Capital Management, LLC8.91071.68425518881-200000-3.4972
2023-12-31RTW INVESTMENTS, LLC8.83170.57675469956-348848-5.9952
2023-12-31COWEN AND COMPANY, LLC5.6091.53813473934-834425-19.3676
2023-12-31Vanguard Group Inc4.06870.00042519984-123211-4.6614
2023-09-30TRV GP IV, LLC3.78323.9196234315400
2023-12-31Goldman Sachs Group Inc2.81420.001117430061483779572.386
2023-12-31BlackRock Inc2.52180.000315618661159288.0175
2023-12-31Adage Capital Partners Gp LLC2.43230.02111506422-900000-37.3999
2023-12-31Jefferies Financial Group Inc2.31420.0631143331600
2023-09-30Citadel Advisors Llc2.0250.00121254184-250455-16.6455
2023-12-31Morgan Stanley - Brokerage Accounts1.96830.0007121905930718833.6877
2023-12-31Logos Global Management LP1.93750.7561120000012000000
2023-12-31Vestal Point Capital LP1.6550.733102500010250000
2023-12-31Dimensional Fund Advisors, Inc.1.57470.001997527941328173.5378
2023-12-31Deutsche Bank AG1.3290.00288230988230980
2023-12-31Propel Bio Management LLC1.21094.19737500007500000
2023-12-31Rock Springs Capital Management LP1.17490.120972767300
2023-12-31Susquehanna International Group, LLP1.07630.000966659316125231.9095
Total 83.160614.846451505724+3331786+6.5%

3.2. Funds holding Fulcrum Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Growth Compy Commingled Pl O2.92270.01821810167266021.4915
2024-02-29Vanguard Total Stock Mkt Idx Inv2.7360.0011169451600
2024-01-31Fidelity Select Biotechnology2.51620.2439155839700
2024-01-31Fidelity Growth Company Fund1.38730.0113859224-8160-0.9408
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.17890.007373016960600.8369
2024-01-31Fidelity Select Pharmaceuticals Port1.10370.530368360000
2024-02-29Invesco Dorsey Wright SmallCap Momt ETF0.8420.5924521498130752.5717
2024-02-29Simplify Propel Opportunities ETF0.75084.069546500000
2024-02-29iShares Biotechnology ETF0.71860.0597445037-2005-0.4485
2024-01-31Fidelity Growth Company K60.71810.0192444767-11042-2.4225
2024-01-31Fidelity Series Growth Company0.50540.0152313041-22560-6.7223
2024-01-31Fidelity Extended Market Index0.44730.005627701028331.0333
2024-01-31DFA US Micro Cap I0.41690.027425821200
2024-02-29abrdn Life Sciences Investors0.41480.59325688800
2024-02-29Simplify Health Care ETF0.27491.64541702654436335.2361
2024-02-29Dimensional US Targeted Value ETF0.21840.014513525200
2024-02-29iShares Micro-Cap ETF0.20860.14481292258730.6802
2023-12-31Bridgeway Ultra-Small Company Market0.20420.459612650000
2024-02-29Dimensional US Core Equity 2 ETF0.19540.004712103965045.6786
2023-09-30BlackRock Extended Mkt Composite0.17940.0035111097-27947-20.0994
Total 17.93968.466611110904+28596+0.3%

3.3. Insider Transactions

Insiders are holding 1.382% of the shares of Fulcrum Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-08Greg TourangeauSELL488411.72
2023-05-10Greg TourangeauSELL2103.31

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Fulcrum Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3270.146-324%-0.051-84%0.129-355%0.181-281%
Book Value Per Share--3.7974.288-11%3.109+22%2.595+46%2.530+50%
Current Ratio--17.71119.123-7%11.679+52%11.311+57%11.606+53%
Debt To Asset Ratio--0.0870.083+5%0.137-36%0.152-43%0.150-42%
Debt To Equity Ratio--0.0960.090+6%0.159-40%0.185-48%0.183-48%
Dividend Per Share----0%-0%0.052-100%0.049-100%
Eps---0.400-0.393-2%-0.443+11%-0.362-9%-0.354-11%
Free Cash Flow Per Share---0.375-0.369-2%-0.400+7%-0.295-21%-0.289-23%
Free Cash Flow To Equity Per Share---0.3710.583-164%-0.059-84%0.223-266%0.205-281%
Gross Profit Margin--1.0211.005+2%1.000+2%1.001+2%1.001+2%
Intrinsic Value_10Y_max---15.227--------
Intrinsic Value_10Y_min---13.169--------
Intrinsic Value_1Y_max---1.469--------
Intrinsic Value_1Y_min---1.443--------
Intrinsic Value_3Y_max---4.457--------
Intrinsic Value_3Y_min---4.254--------
Intrinsic Value_5Y_max---7.497--------
Intrinsic Value_5Y_min---6.955--------
Market Cap441597976.000+5%418062600.000268489092.000+56%680048496.000-39%627310673.200-33%597438736.381-30%
Net Profit Margin---28.423-40.093+41%-20.705-27%-15.348-46%-14.617-49%
Operating Margin---32.138-48.984+52%-22.411-30%-17.518-45%-16.684-48%
Operating Ratio--33.13850.319-34%23.762+39%18.441+80%17.563+89%
Pb Ratio1.878+5%1.7781.048+70%3.540-50%4.528-61%4.313-59%
Pe Ratio-4.460-6%-4.222-2.753-35%-6.485+54%-7.769+84%-7.399+75%
Price Per Share7.130+5%6.7504.335+56%10.980-39%10.129-33%9.646-30%
Price To Free Cash Flow Ratio-4.751-6%-4.498-2.936-35%-7.291+62%-11.148+148%-10.617+136%
Price To Total Gains Ratio-21.787-6%-20.626-10.599-49%-21.985+7%-15.845-23%-15.845-23%
Quick Ratio--32.84335.451-7%19.855+65%17.833+84%17.809+84%
Return On Assets---0.096-0.082-14%-0.123+28%-0.140+46%-0.138+44%
Return On Equity---0.105-0.090-15%-0.144+37%-0.168+59%-0.165+57%
Total Gains Per Share---0.3270.146-324%-0.051-84%0.180-282%0.230-242%
Usd Book Value--235193000.000265584750.000-11%192567750.000+22%160725750.000+46%156691190.476+50%
Usd Book Value Change Per Share---0.3270.146-324%-0.051-84%0.129-355%0.181-281%
Usd Book Value Per Share--3.7974.288-11%3.109+22%2.595+46%2.530+50%
Usd Dividend Per Share----0%-0%0.052-100%0.049-100%
Usd Eps---0.400-0.393-2%-0.443+11%-0.362-9%-0.354-11%
Usd Free Cash Flow---23235000.000-22868250.000-2%-24753250.000+7%-18300500.000-21%-17899000.000-23%
Usd Free Cash Flow Per Share---0.375-0.369-2%-0.400+7%-0.295-21%-0.289-23%
Usd Free Cash Flow To Equity Per Share---0.3710.583-164%-0.059-84%0.223-266%0.205-281%
Usd Market Cap441597976.000+5%418062600.000268489092.000+56%680048496.000-39%627310673.200-33%597438736.381-30%
Usd Price Per Share7.130+5%6.7504.335+56%10.980-39%10.129-33%9.646-30%
Usd Profit---24756000.000-23543500.000-5%-26861000.000+9%-21798050.000-12%-21181904.762-14%
Usd Revenue--871000.000701250.000+24%1585500.000-45%1856650.000-53%1768238.095-51%
Usd Total Gains Per Share---0.3270.146-324%-0.051-84%0.180-282%0.230-242%
 EOD+5 -3MRQTTM+10 -24YOY+19 -155Y+12 -2410Y+12 -24

4.2. Fundamental Score

Let's check the fundamental score of Fulcrum Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.460
Price to Book Ratio (EOD)Between0-11.878
Net Profit Margin (MRQ)Greater than0-28.423
Operating Margin (MRQ)Greater than0-32.138
Quick Ratio (MRQ)Greater than132.843
Current Ratio (MRQ)Greater than117.711
Debt to Asset Ratio (MRQ)Less than10.087
Debt to Equity Ratio (MRQ)Less than10.096
Return on Equity (MRQ)Greater than0.15-0.105
Return on Assets (MRQ)Greater than0.05-0.096
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Fulcrum Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.730
Ma 20Greater thanMa 507.976
Ma 50Greater thanMa 1009.350
Ma 100Greater thanMa 2008.044
OpenGreater thanClose7.070
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets257,694
Total Liabilities22,501
Total Stockholder Equity235,193
 As reported
Total Liabilities 22,501
Total Stockholder Equity+ 235,193
Total Assets = 257,694

Assets

Total Assets257,694
Total Current Assets242,199
Long-term Assets15,495
Total Current Assets
Cash And Cash Equivalents 25,563
Short-term Investments 210,658
Net Receivables 2,249
Other Current Assets 3,729
Total Current Assets  (as reported)242,199
Total Current Assets  (calculated)242,199
+/-0
Long-term Assets
Property Plant Equipment 12,392
Long-term Assets Other 2,011
Long-term Assets  (as reported)15,495
Long-term Assets  (calculated)14,403
+/- 1,092

Liabilities & Shareholders' Equity

Total Current Liabilities13,675
Long-term Liabilities8,826
Total Stockholder Equity235,193
Total Current Liabilities
Short-term Debt 2,192
Accounts payable 2,757
Other Current Liabilities 8,726
Total Current Liabilities  (as reported)13,675
Total Current Liabilities  (calculated)13,675
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt8,629
Long-term Liabilities Other 197
Long-term Liabilities  (as reported)8,826
Long-term Liabilities  (calculated)8,826
+/-0
Total Stockholder Equity
Common Stock62
Retained Earnings -509,673
Accumulated Other Comprehensive Income -136
Other Stockholders Equity 744,940
Total Stockholder Equity (as reported)235,193
Total Stockholder Equity (calculated)235,193
+/-0
Other
Capital Stock62
Cash and Short Term Investments 236,221
Common Stock Shares Outstanding 61,871
Liabilities and Stockholders Equity 257,694
Net Debt -14,742
Net Invested Capital 235,193
Net Working Capital 228,524
Property Plant and Equipment Gross 25,152
Short Long Term Debt Total 10,821



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
85,771
75,588
65,151
115,956
110,439
94,856
144,862
142,215
129,577
156,476
137,879
255,547
235,000
220,248
195,233
247,805
226,685
321,120
300,332
278,879
257,694
257,694278,879300,332321,120226,685247,805195,233220,248235,000255,547137,879156,476129,577142,215144,86294,856110,439115,95665,15175,58885,771000
   > Total Current Assets 
0
0
0
74,095
63,996
51,366
105,222
100,083
84,323
134,784
132,112
112,914
146,987
128,511
246,187
225,998
200,064
174,247
227,727
207,519
302,830
282,947
262,490
242,199
242,199262,490282,947302,830207,519227,727174,247200,064225,998246,187128,511146,987112,914132,112134,78484,323100,083105,22251,36663,99674,095000
       Cash And Cash Equivalents 
0
0
0
72,797
62,452
49,628
101,597
96,713
25,379
75,718
85,221
57,052
100,745
56,779
65,473
35,412
33,313
40,153
90,938
35,098
34,734
33,966
30,080
25,563
25,56330,08033,96634,73435,09890,93840,15333,31335,41265,47356,779100,74557,05285,22175,71825,37996,713101,59749,62862,45272,797000
       Short-term Investments 
0
0
0
0
0
0
0
0
55,828
56,020
41,804
55,862
43,111
68,771
174,872
182,750
161,799
128,820
130,851
167,823
263,106
244,198
227,011
210,658
210,658227,011244,198263,106167,823130,851128,820161,799182,750174,87268,77143,11155,86241,80456,02055,82800000000
       Net Receivables 
0
0
0
501
489
96
159
111
502
960
663
2,707
634
823
1,558
4,110
1,208
1,492
1,237
1,081
1,264
2,070
1,679
2,249
2,2491,6792,0701,2641,0811,2371,4921,2084,1101,5588236342,70766396050211115996489501000
       Other Current Assets 
0
0
0
238
318
211
305
284
291
208
72
74
258
11
38
5,336
47
3,782
4,701
4,369
4,891
4,127
4,819
3,729
3,7294,8194,1274,8914,3694,7013,782475,33638112587472208291284305211318238000
   > Long-term Assets 
0
0
0
11,676
11,592
13,785
10,734
10,356
10,533
10,078
10,103
16,663
9,489
9,368
9,360
9,002
20,184
20,986
20,078
19,166
18,290
17,385
16,389
15,495
15,49516,38917,38518,29019,16620,07820,98620,1849,0029,3609,3689,48916,66310,10310,07810,53310,35610,73413,78511,59211,676000
       Property Plant Equipment 
0
0
0
10,546
10,225
10,005
9,583
87,943
9,362
8,910
8,395
8,397
7,834
7,745
7,749
7,368
18,276
17,788
16,888
15,969
15,167
14,298
13,307
12,392
12,39213,30714,29815,16715,96916,88817,78818,2767,3687,7497,7457,8348,3978,3958,9109,36287,9439,58310,00510,22510,546000
       Other Assets 
0
0
0
0
1,367
3,780
1,151
1,151
1,171
1,168
1,708
1,670
1,655
1,623
1,611
1,634
1,908
3,198
3,190
3,197
0
3,087
0
0
003,08703,1973,1903,1981,9081,6341,6111,6231,6551,6701,7081,1681,1711,1511,1513,7801,3670000
> Total Liabilities 
0
0
0
9,771
10,139
11,696
13,828
23,286
24,225
22,731
37,230
34,396
28,722
26,989
24,938
23,461
31,088
34,478
26,391
27,743
24,864
24,904
23,417
22,501
22,50123,41724,90424,86427,74326,39134,47831,08823,46124,93826,98928,72234,39637,23022,73124,22523,28613,82811,69610,1399,771000
   > Total Current Liabilities 
0
0
0
4,229
4,690
6,343
8,585
12,140
14,182
13,943
26,455
26,725
22,631
22,510
20,597
19,199
18,288
22,121
14,699
16,725
14,407
14,804
14,075
13,675
13,67514,07514,80414,40716,72514,69922,12118,28819,19920,59722,51022,63126,72526,45513,94314,18212,1408,5856,3434,6904,229000
       Short-term Debt 
0
0
0
46
47
48
49
50
51
43
30
17
4
8,070
10,667
469
2,426
2,484
2,543
2,602
2,663
2,507
2,350
2,192
2,1922,3502,5072,6632,6022,5432,4842,42646910,6678,0704173043515049484746000
       Accounts payable 
0
0
0
1,263
2,522
3,081
4,533
2,186
3,937
3,571
3,634
4,079
4,797
4,498
3,742
4,788
6,003
5,385
2,728
3,638
3,778
3,909
3,574
2,757
2,7573,5743,9093,7783,6382,7285,3856,0034,7883,7424,4984,7974,0793,6343,5713,9372,1864,5333,0812,5221,263000
       Other Current Liabilities 
0
0
0
120
51
58
61
5,915
5,637
5,865
9,182
7,719
5,701
42
57
9,231
6,939
12,470
8,039
9,551
7,229
7,875
7,817
8,726
8,7267,8177,8757,2299,5518,03912,4706,9399,23157425,7017,7199,1825,8655,6375,915615851120000
   > Long-term Liabilities 
0
0
0
5,542
5,449
5,353
5,243
11,146
10,043
8,788
10,775
7,671
6,091
4,479
4,341
4,262
12,800
12,357
11,692
11,018
10,457
10,100
9,342
8,826
8,8269,34210,10010,45711,01811,69212,35712,8004,2624,3414,4796,0917,67110,7758,78810,04311,1465,2435,3535,4495,542000
       Other Liabilities 
0
0
0
0
5,449
5,353
5,243
11,125
10,043
8,788
10,775
7,671
6,091
4,479
4,341
4,262
12,800
197
197
197
0
447
0
0
00447019719719712,8004,2624,3414,4796,0917,67110,7758,78810,04311,1255,2435,3535,4490000
       Deferred Long Term Liability 
0
0
0
0
0
2,064
0
0
0
0
0
4,620
3,157
1,662
1,642
0
0
0
0
0
4,620
0
0
0
0004,620000001,6421,6623,1574,620000002,06400000
> Total Stockholder Equity
-33,265
0
0
76,000
65,449
53,455
102,128
87,153
70,631
122,131
104,985
95,181
127,754
110,890
230,609
211,539
189,160
160,755
221,414
198,942
296,256
275,428
255,462
235,193
235,193255,462275,428296,256198,942221,414160,755189,160211,539230,609110,890127,75495,181104,985122,13170,63187,153102,12853,45565,44976,00000-33,265
   Common Stock
0
0
0
16
18
2
23
23
23
27
27
28
33
33
41
41
41
41
52
52
62
62
62
62
62626262525241414141333328272723232321816000
   Retained Earnings Total Equity000-437,117-412,338-386,203-362,465-328,395-302,467-278,983-258,267-238,619-221,62000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-1,958
-2,398
-2,912
-3,427
-3,947
-53
81
31
-2
-4
-9
-87
-397
-1,090
-1,068
-921
-797
-651
-1,200
-886
-136
-136-886-1,200-651-797-921-1,068-1,090-397-87-9-4-23181-53-3,947-3,427-2,912-2,398-1,958000
   Capital Surplus 
0
0
0
0
5,268
6,453
236,783
237,931
239,914
0
0
316,775
366,344
369,133
509,638
514,362
518,604
524,247
608,486
612,025
733,962
0
0
0
000733,962612,025608,486524,247518,604514,362509,638369,133366,344316,77500239,914237,931236,7836,4535,2680000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
146,066
172,796
9,365
124,254
241,878
239,914
306,961
308,827
316,775
366,344
369,133
509,638
514,362
518,604
524,247
608,486
612,025
733,962
737,466
741,203
744,940
744,940741,203737,466733,962612,025608,486524,247518,604514,362509,638369,133366,344316,775308,827306,961239,914241,878124,2549,365172,796146,066000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,805
Cost of Revenue-2,172
Gross Profit633633
 
Operating Income (+$)
Gross Profit633
Operating Expense-111,297
Operating Income-110,664-110,664
 
Operating Expense (+$)
Research Development71,801
Selling General Administrative41,668
Selling And Marketing Expenses2,172
Operating Expense111,297115,641
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-110,664
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-97,335-123,993
EBIT - interestExpense = -110,664
-97,335
-97,335
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-110,664-97,335
Earnings Before Interest and Taxes (EBITDA)-108,492
 
After tax Income (+$)
Income Before Tax-97,335
Tax Provision-0
Net Income From Continuing Ops-98,714-97,335
Net Income-97,335
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses113,469
Total Other Income/Expenses Net13,3290
 

Technical Analysis of Fulcrum Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Fulcrum Therapeutics Inc. The general trend of Fulcrum Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Fulcrum Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Fulcrum Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 13.22 < 13.70 < 14.10.

The bearish price targets are: 6.645 > 6.64 > 6.4.

Tweet this
Fulcrum Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Fulcrum Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Fulcrum Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Fulcrum Therapeutics Inc. The current macd is -0.64618914.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Fulcrum Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Fulcrum Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Fulcrum Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Fulcrum Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartFulcrum Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Fulcrum Therapeutics Inc. The current adx is 34.17.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Fulcrum Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Fulcrum Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Fulcrum Therapeutics Inc. The current sar is 6.704056.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Fulcrum Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Fulcrum Therapeutics Inc. The current rsi is 31.73. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Fulcrum Therapeutics Inc Daily Relative Strength Index (RSI) ChartFulcrum Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Fulcrum Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Fulcrum Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Fulcrum Therapeutics Inc Daily Stochastic Oscillator ChartFulcrum Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Fulcrum Therapeutics Inc. The current cci is -83.44732739.

Fulcrum Therapeutics Inc Daily Commodity Channel Index (CCI) ChartFulcrum Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Fulcrum Therapeutics Inc. The current cmo is -38.6587286.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Fulcrum Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartFulcrum Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Fulcrum Therapeutics Inc. The current willr is -77.99043062.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Fulcrum Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Fulcrum Therapeutics Inc Daily Williams %R ChartFulcrum Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Fulcrum Therapeutics Inc. The current atr is 0.50714789.

Fulcrum Therapeutics Inc Daily Average True Range (ATR) ChartFulcrum Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Fulcrum Therapeutics Inc. The current obv is 51,560,063.

Fulcrum Therapeutics Inc Daily On-Balance Volume (OBV) ChartFulcrum Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Fulcrum Therapeutics Inc. The current mfi is 15.01.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Fulcrum Therapeutics Inc Daily Money Flow Index (MFI) ChartFulcrum Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Fulcrum Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Fulcrum Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Fulcrum Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.730
Ma 20Greater thanMa 507.976
Ma 50Greater thanMa 1009.350
Ma 100Greater thanMa 2008.044
OpenGreater thanClose7.070
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Fulcrum Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Fulcrum Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Fulcrum Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Fulcrum Therapeutics Inc

I send you an email if I find something interesting about Fulcrum Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Fulcrum Therapeutics Inc.

Receive notifications about Fulcrum Therapeutics Inc in your mailbox!